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Abstract
Background and Aim: The identification of gastric carcinomas (GC) has traditionally
been based on histomorphology. Recently, DNA microarrays have successfully been used
to identify tumors through clustering of the expression profiles. Random forest clustering
is widely used for tissue microarrays and other immunohistochemical data, because it
handles highly-skewed tumor marker expressions well, and weighs the contribution of each
marker according to its relatedness with other tumor markers. In the present study, we e
identified biologically- and clinically-meaningful groups of GC by hierarchical clustering
analysis of immunohistochemical protein expression.
Methods: We selected 28 proteins (p16, p27, p21, cyclin D1, cyclin A, cyclin B1, pRb,
p53, c-met, c-erbB-2, vascular endothelial growth factor, transforming growth factor
[TGF]-bI, TGF-bII, MutS homolog-2, bcl-2, bax, bak, bcl-x, adenomatous polyposis coli,
clathrin, E-cadherin, b-catenin, mucin (MUC)1, MUC2, MUC5AC, MUC6, matrix met-
alloproteinase [MMP]-2, and MMP-9) to be investigated by immunohistochemistry in 482
GC. The analyses of the data were done using a random forest-clustering method.
Results: Proteins related to cell cycle, growth factor, cell motility, cell adhesion, apoptosis,
and matrix remodeling were highly expressed in GC. We identified protein expressions
associated with poor survival in diffuse-type GC.
Conclusions: Based on the expression analysis of 28 proteins, we identified two groups of
GC that could not be explained by any clinicopathological variables, and a subgroup of
long-surviving diffuse-type GC patients with a distinct molecular profile. These results
provide not only a new molecular basis for understanding the biological properties of GC,
but also better prediction of survival than the classic pathological grouping.
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Introduction
Gastric carcinoma (GC) is caused by multiple molecular and
genetic alterations that underlie the malignant transformation of
gastric mucosa.1 The main molecular and genetic alterations
include microsatellite instability, inactivation of tumor suppressor
genes, such as TP53, p16, adenomatous polyposis coli, Deleted in
Colorectal Cancer, and fragile histidine triad, and the activation of
oncogenes, such as human epidermal growth factor receptor-2,
Ras, c-myc, cyclin E, and K-sam1. However, these genetic changes
do not precisely reflect the biological nature of the tumor cells or
the clinical characteristics of GC patients.
Recently, large-scale molecular technologies, such as DNA
microarrays, have enabled the global monitoring of gene expres-
sion changes.2 Several extensive global gene expression studies
have already been reported for GC.3–6 Previous studies have
described the differences between gastric tumors and normal
samples,5,6 as well as the process of gastric carcinogenesis, using
gene expression profiling.3,7 This has permitted a preliminary
selection of classifiers of the subtypes7,8 and the identification of
new molecular subtypes.9 However, such high-throughput experi-
ments often generate hundreds of candidate genes or proteins,
sometimes with futile results. The cost, complexity, and interpre-
tation of DNA microarrays are currently unsuitable for routine
use in standard clinical settings. Recently, in large-scale molecu-
lar studies, formalin-fixed, embedded fixed tissue using immu-
nohistochemistry and clustering analysis of multiple markers
have been reported to be significantly correlated with patient sur-
vival.10,11 In addition, previous results have demonstrated that
protein expressions are likely to have a more direct impact on the
biological behaviors of GC than expressions at the DNA and
RNA levels.12
In the present study, we identified biologically- and clinically-
meaningful groups of GC by hierarchical analysis of 28 selected
doi:10.1111/j.1440-1746.2011.06849.x
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protein expressions, previously described to be either putative
tumor suppressors or involved in GC progression using tissue
microarray (TMA) and immunohistochemistry.
Methods
Specimens
A total of 482 cases of primary GC surgically treated from 1980
to 1998 were identified in the files of the Department of Pathol-
ogy, A. C. Camargo Hospital (Sao Paulo, Brazil). All the cases
(mean age: 62 years, range: 26–84 years; 308 males and 174
females) failed to accept radiotherapy or chemotherapy neoadju-
vant. The study items included age, sex, tumor location, tumor
size, and pathological tumor lymph node metastasis (pTNM)
stage. The clinical characteristics and pathological findings are
summarized in Table 1. Tissue slides were reviewed for histo-
logical classification, according to Lauren’s classification.13 The
series included 234 intestinal type, 166 diffuse type, 22 mixed
type, and 60 cases of unclassified type. Patient clinical outcome
was followed up from the date of surgery up to a period of 0.6–
108.6 months (mean: 28.3 months). Patients who were lost to
Table 2 Antibodies used for immunohistochemistry
Antibody Clones Source Dilution Expression patterns
b-catenin 17C2 Novocastra 1:100 Membranous
APC Polyclonal Santa Cruz Biotechnologies 1:800 Cytoplasm
Bak Polyclonal Dako 1:400 Cytoplasm
Bax Polyclonal Dako 1:50 Cytoplasm
Bcl-2 124 Dako 1:40 Cytoplasm
Bcl-x Polyclonal Dako 1:50 Cytoplasm
c-erbB-2 Polyclonal DAKO 1:500 Membranous
Clathrin 23 BD Transduction 1:2000 Cytoplasm
C-met Polyclonal Novocastra 1:50 Membranous
Cyclin A Polyclonal Santa Cruz Biotechnologies 1:40 Nuclear
Cyclin B1 V152 DAKO 1:50 Cytoplasm
Cyclin D1 RBT-14 BIO SB Read to use Nuclear
E-cadherin 36B5 Novocastra 1:50 Membranous
MMP-2 75-7F7 Oncogene 1:40 Cytoplasm
MMP-9 56-2A4 Oncogene 1:80 Cytoplasm
MSH-2 Polyclonal Santa Cruz 1:25 Nuclear
MUC1 Ma695 Novocastra 1:500 Cytoplasm
MUC2 CCp58 Novocastra 1:1000 Cytoplasm
MUC5AC CLH2 Novocastra 1:500 Cytoplasm
MUC6 CLH5 Novocastra 1:600 Cytoplasm
NOS-1 nNOS Santa Cruz Biotechnologies 1:200 Cytoplasm
NOS-2 iNOS Santa Cruz Biotechnologies 1:40 Cytoplasm
NOS-3 eNOS Santa Cruz Biotechnologies 1:100 Cytoplasm
p16 C-20 MTM 1:25 Nuclear
p21 SX118 DAKO 1:30 Nuclear
p27 SX53G8 DAKO 1:200 Nuclear
p53 DO7 DAKO 1:100 Nuclear
pRb Rb1 DAKO 1:50 Nuclear
TFG-bI Polyclonal Santa Cruz Biotechnologies 1:50 Cytoplasm
TFG-bII Polyclonal Santa Cruz Biotechnologies 1:200 Cytoplasm
VEGF Polyclonal Santa Cruz Biotechnologies 1:500 Cytoplasm
APC, matrix metalloproteinase; MMP, matrix metalloproteinase; MSH-2, MutS homolog-2; MUC, mucin; NOS, nitric oxide synthase; TGF, transform-
ing growth factor; VEGF, vascular endothelial growth factor.
Table 1 Clinical characteristics and histopathological findings of 482
gastric carcinomas
Variable Category No. cases (%)
Sex Male 308 (64%)
Female 174 (36%)
Age < 60 years 273 (56%)
> 60 years 209 (44%)
Tumor size < 5 cm 198 (41%)
> 5 cm 284 (59%)
Location Proximal 48 (10%)
Distal 407 (84%)
Whole stomach 27 (6%)
Depth of infiltration Tis-T1 27 (6%)
T2-4 455 (94%)
Lymph node metastases Present 358 (75%)
Absent 119 (25%)
Histological type Intestinal 234 (48.5%)
Diffuse 166 (34%)
Mixed 60 (12%)
Unclassified 22 (4.5%)
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follow up or who died from any other cause than GC were
regarded as censored data for the analysis of the survival rates.
No hereditary tumors or tumors associated with specific genetic
mutations were included. The institutional board for ethical
studies at A. C. Camargo Hospital approved this study.
TMA methods
Three array blocks, containing a total of 482 cases, were prepared,
as described previously. Using a tissue microarrayer (Beecher
Instruments, Silver Spring, MD, USA), core tissue biopsies
(0.6 mm diameter) were taken from individual paraffin-embedded
GC (donor blocks) and transferred to a recipient paraffin block
(tissue array blocks). The area of interest in the donor block was
cored twice, and the cores (n = 964) were arrayed onto three sepa-
rate blocks that contained two tumor cores from each case. Sub-
sequently, 4-mm-thick sections were cut from each tissue array
block, deparaffinized, and dehydrated.
Immunohistochemistry
A standard peroxidase-conjugated streptavidin–biotin method was
used to detect the staining reaction against tumor-associated gene
products. Commercially-available antibodies were tested using a
stomach cancer control slide. After the test procedure, 28 antibod-
ies, which were properly stained in each positive and negative
control, were selected for this study. The primary antibodies
studied are described in Table 2. The immunohistochemical stain-
ing was evaluated by means of light microscopic examination, and
interpreted by two independent pathologists who were blinded to
clinical information. The final consensus was discussed and deter-
mined in a common session. For the statistical analysis, the cases
were considered positive when the tumor cells showed a dark
brown color in more than 10% of the neoplastic cells.11 Immuno-
histochemistry was done in two slides of the three blocks of TMA
for each antibody.
Cluster analyses
Cluster analyses were used to identify the similarity profile of
variations with our data. In this study, hierarchical cluster analyses
were done using a random forest-clustering method (TMEV, http://
www.tm4.org/mev.html), and results were displayed using Tree-
View.14 This method is an unsupervised learning method that aims
to find molecular classifications with distinct global expression
profiles blinded to clinicopathological covariates.
Statistical analyses
The survival curves were estimated using the Kaplan–Meier
product-limit method, and the significant differences between the
survival curves were determined using the log–rank test. Multi-
variate survival analysis was performed using the Cox propor-
tional hazards model. The correlation coefficients between the
immunohistochemical expression status and clinicopathological
findings, as well as between every antibody expression status,
were estimated by Pearson’s correlation. The c2-test or Fisher’s
exact test (two sided) was performed to determine the correlation
between the antibodies expression and clinicopathological param-
eters. The results were considered to be statistically significant at
P < 0.05. All statistical analyses were conducted using the SPSS
10.0 statistical software program (SPSS, Chicago, IL, USA).
Results
Immunohistochemical findings
The staining results of the 28 antibodies are summarized in
Table 3. For most of the antibodies tested, there was a significant
difference in immunostaining between the diffuse- and intestinal-
type GC. Of the 28 proteins studied, 13 were more often immu-
nopositive in intestinal-type GC: clathrin (P < 0.001), E-cadherin
(P = 0.001), matrix metalloproteinase-2 (P = 0.019), p21
(P = 0.007), p53 (P = 0.001), transforming growth factor
(TGF)-bI (P = 0.005), TGF-bII (P = 0.018), c-erbB-2 (P < 0.001),
vascular endothelial growth factor (VEGF; P < 0.001), MutS
homolog-2 (P < 0.001), and nitric oxide-3 (P = 0.002). However,
Table 3 Expression of the 28 proteins and association with histological
subtype of gastric carcinomas
Antibody Category Histological subtype P-value
Intestinal Diffuse Total
E-cadherin Positive 87 (39%) 11 (7%) 98 (100%) #0.001
Negative 137 (61%) 144 (93%) 281 (100%)
MUC2 Negative 212 (93%) 128 (82%) 340 (100%) 0.001
Positive 14 (7%) 29 (18%) 43 (100%)
Clathrin Negative 56 (25%) 86 (54%) 142 (100%) < 0.001
Positive 172 (75%) 73 (46%) 245 (100%)
MMP-2 Negative 123 (54%) 101 (66%) 224 (100%) 0.019
Positive 104 (46%) 51 (34%) 155 (100%)
Cyclin B1 Negative 119 (52%) 64 (41%) 183 (100%) 0.029
Positive 107 (48%) 92 (59%) 199 (100%)
pRb Negative 86 (39%) 36 (23%) 122 (100%) 0.002
Positive 138 (61%) 121 (77%) 259 (100%)
p21 Negative 189 (84%) 144 (93%) 333 (100%) 0.007
Positive 37 (16%) 11 (7%) 48 (100%)
p53 Negative 146 (65%) 118 (76%) 264 (100%) 0.001
Positive 80 (35%) 36 (24%) 116 (100%)
TGF-bI Negative 31 (14%) 40 (25%) 71 (100%) 0.005
Positive 197 (86%) 117 (75%) 314 (100%)
TGF-bII Negative 3 (2%) 9 (6%) 12 (100%) 0.018
Positive 223 (98%) 147 (94%) 370 (100%)
c-erbB-2 Negative 177 (78%) 154 (97%) 331 (100%) < .001
Positive 49 (22%) 5 (3%) 54 (100%)
c-Met Negative 17 (8%) 25 (16%) 42 (100%) 0.012
Positive 208 (92%) 129 (84%) 333 (100%)
VEGF Negative 10 (8%) 23 (15%) 33 (100%) < 0.001
Positive 207 (92%) 126 (85%) 333 (100%)
MSH-2 Negative 6 (3%) 24 (15%) 30 (100%) < 0.001
Positive 220 (97%) 136 (85%) 356 (100%)
NOS-3 Negative 2 (1%) 11 (8%) 13 (100%) 0.002
Positive 215 (99%) 137 (92%) 352 (100%)
MMP-2, matrix metalloproteinase-2; MSH-2, MutS homolog-2; MUC2,
mucin2; NOS-3, nitric oxide synthase-3; TGF, transforming growth
factor; VEGF, vascular endothelial growth factor.
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the following were more often immunopositive in diffuse-type
GC: mucin2 (MUC2) (P = 0.001), cyclin B1 (P = 0.029), and pRb
(P = 0.002).
Hierarchical cluster analysis
The overall expression patterns for the 460 samples of GC were
analyzed by hierarchical clustering after excluding those with
values missing in more than 20% of the columns. The combined
protein expression patterns defined two clusters: cluster A (228
cases) and cluster B (232 cases; Fig. 1). Cluster A consisted of
tumors frequently negative for proteins related to cell-cycle
control and apoptosis (e.g. Bcl-x, Bak, Bcl-2, cyclins), whereas
cluster B consisted of tumors more often positive for suppressor
proteins (e.g. p21, p16, p53, E-cadherin).
Significant associations between clusters and clinicopathologi-
cal findings, such as sex, age, location, and histological tumor
type, were not observed. However, cluster B was significantly
correlated with advanced pTNM stage (P = 0.046, c2). All of the
data are summarized in Table 4.
Previous studies have indicated distinct genetic changes and an
expression pattern of a subset of genes and proteins between the
histological subtypes of GC. To identify novel genes and proteins
associated with the histological subtypes, we performed a separate
clustering analysis of the protein expression in the two major types
(intestinal and diffuse). A total of 116 diffuse-type GC and 344
intestinal-type GC were studied. The tumors were separated into
three main clusters (Figs 2a,3a).
To determine whether these clusters might represent clinically
distinct subgroups of patients, a univariate survival analysis was
carried out. In the group of diffuse-type tumors, cluster A was
associated with poorer prognosis, when compared with clusters B
and C. The rate of overall survival time was 50.8% for patients in
cluster C, 36.1% for patients in cluster B, and 12.3% for patients
in cluster A. These differences were statistically significant
(P = 0.001, Fig. 2b). Cluster C was characterized by tumors
Figure 1 Two-way hierarchical cluster analysis of 482 gastric carcinomas according to the expression of 28 proteins. Tumors were grouped into
three clusters, based on the protein expression profile. Rows represent proteins ordered according to their hierarchical distances. Colors in columns
represent expression levels: red indicates positive staining, and green represents the absence of staining for each of the antibodies studied. Within
each cluster, samples were ordered on the basis of their correlation distances.
Table 4 Associations between clusters and clinicopathological features in gastric carcinomas
Variable Category Cluster A Cluster B Total P-value
Sex Male 138 (48%) 154 (52%) 292 (100%) NS
Female 90 (54%) 78 (46%) 168 (100%)
Age < 60 years 129 (50%) 130 (50%) 259 (100%) NS
> 60 years 99 (49%) 102 (51%) 201 (100%)
Tumor size < 5 cm 102 (54%) 86 (46%) 188 (100%) NS
> 5 cm 126 (46%) 146 (54%) 272 (100%)
Dept of infiltration T2-4 221 (50%) 218 (50%) 340 (100%) NS
Tis-T1 7 (33%) 14 (67%) 21 (100%)
Lymph node metastases Present 175 (51%) 167 (49%) 342 (100%) NS
Absent 52 (46%) 61 (54%) 113 (100%)
Location Distal 192 (50%) 194 (50%) 386 (100%) NS
Proximal 23 (48%) 25 (52%) 48 (100%)
Whole stomach 13 (52%) 12 (48%) 25 (100%)
Histological type Intestinal 100 (44%) 126 (56%) 226 (100%) NS
Diffuse 88 (56%) 68 (44%) 156 (100%)
Mixed 28 (48%) 30 (52%) 58 (100%)
Unclassified 12 (60%) 8 (40%) 20 (100%)
Clinical stage I and II 135 (53%) 121 (47%) 256 (100%) 0.046
III and IV 61 (42%) 83 (58%) 144 (100%)
NS, not significant.
MD Begnami et al. Molecular markers in gastric cancer
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frequently negative for most of the proteins studied. Interestingly,
they were positive only for MUC2, TGF-bII, and cyclin B1.
Kaplan–Meier curves did not show any differences between the
clusters in the intestinal tumor of GC (P = 0.328, Fig. 3b).
Discussion
GC is associated with various genetic alterations, and no single
genetic marker can predict the biology and prognosis of patients
with GC. The potential use of combinations of biomarkers instead
of a single marker or histological feature has been previously
demonstrated.11,15 Previous studies have applied tissue array
methods for the molecular classifications of various tumors, such
as endometrial, breast, and brain tumors,10,16,17 and protein expres-
sion profiling has been found to be clinically useful for the prog-
nostic classification of tumors.11,15 In this study, we have shown
that a molecular classification of GC can be accomplished based
on a hierarchical cluster analysis of the immunohistochemical
profiles of tumor-associated biomarkers using TMA sections.
Studies on the molecular pathology of GC have largely been
focused on the subtypes of GC: intestinal and diffuse.1,18,19 Several
regulatory genes and molecular pathways, including regulation of
Figure 2 Classification of diffuse gastric car-
cinomas based on the expression of the 28
proteins. (a) Matrix format presenting the
whole data. In the data matrix, a row corre-
sponds to a single protein, and each column
corresponds to a single tumor. Tumors were
grouped into three clusters, based on the
protein expression profile. Red denotes
positive staining, and green denotes the
absence of staining. (b) Univariate survival
analysis by Kaplan–Meier method. P = 0.001.
(b) , Cluster A; , Cluster
B; , Cluster C.
Figure 3 Classification of intestinal gastric
carcinomas based on the expression of the 28
proteins. (a) Tumors were grouped into three
clusters, based on the protein expression
profile. Red denotes positive staining, and
green denotes the absence of staining. (b)
Univariate survival analysis by Kaplan–Meier
method. P = 0.610. (b) , Cluster A;
, Cluster B; , Cluster C.
Molecular markers in gastric cancer MD Begnami et al.
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the cell cycle, DNA repair, cell adhesion, angiogenesis, apoptosis,
and matrix remodeling, have been extensively studied in GC.6,20
Boussioutas et al. found distinct expression profiles between
intestinal- and diffuse-type GC3. The upregulated genes in the
intestinal-type GC were observed to be mediators of cell prolif-
eration, including genes active in cell-cycle control, DNA replica-
tion, and arrangement of chromosomes, while genes associated
with epithelial differentiation were downregulated.3 Our results,
based on immunohistochemistry, demonstrated various proteins
related to these molecular mechanisms more frequently positive in
the intestinal-type than in diffuse-type GC, such as TGF-bI, TGF-
bII, c-erbB-2, p21, p53, and VEGF. In contrast, diffuse-type GC
was characterized by the expression of MUC2, cyclin D1, and
pRb. In addition, losses of adhesion molecules, such as
E-cadherin, were more frequent in the diffuse-type than in
intestinal-type GC. In line with our results, it has been shown that
diffuse-type GC gene expression changes were found in genes of
the extracellular matrix components (collagens and proteoglycan),
smooth muscles, and their extracellular stroma.3
Hierarchical clustering analysis is a method of dealing with
complex sets of data and offers a possible systematic approach to
complex immunophenotypes. Clustering analysis has been suc-
cessfully applied to gene expression data, based on the expression
of thousands of genes, and has been remarkably successful in its
ability to group tumors according to their primary site based on
gene expression profile.21–23 The clustering of tumors based on
immunoreactivity is expected to be less defined than the gene
expression array studies. This application of clustering analysis
allows for a more objective interpretation of immunoprofiles based
on staining with multiple antibodies, and holds great promise for
the immunohistochemical classification of tumors.16
The overall protein expression patterns defined two main clus-
ters, that is, cluster A (228 cases) and cluster B (232 cases).
Although there was no survival-associated cluster, they demon-
strated specific protein profiles that could be important for using
target therapies. For example, patients in cluster A will not benefit
from using drugs that have anti-apoptotic or cell-cycle inhibitor
activities, because they were frequently negative for the proteins
related to these molecular mechanisms. Moreover, we found that
cluster B mainly comprised advanced tumors (stages III and IV),
and the principal expression proteins were associated with gene
suppressor. Although our results are promising, further validation
is needed concerning the use of these classifiers for screening tests
for treatment selection.
Using a hierarchical cluster analysis of the immunohistochemi-
cal profiles of the diffuse-type (n = 116) and intestinal-type
(n = 344) GC, we found three distinct subgroups of the tumors.
Patients with cluster C diffuse-type GC were found to have the
best prognosis among the three clusters (P = 0.001). They were
characterized by immunoexpression of cyclin D1, MUC2, and
TGF-bII. However, patients with intestinal-type GC did not show
any differences related to the prognosis, which might probably be
due to the more heterogeneous nature of this type of GC. The fact
that the random forest method was able to create clinically mean-
ingful subgroups of tumors using protein expression signature
provides indirect evidence that the method works well on real data.
Using this method, we were able to discover novel, molecularly-
defined patients group who might not have been identified using
traditional clinicopathological features.
Although preliminary, these results not only provide a new
molecular basis for understanding the biological properties of GC,
but also better prediction of survival than the classical pathological
grouping. Further validation across different institutions and tech-
nological platforms is needed concerning the use of the above
classifiers for routine pathological diagnoses.
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